Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

NK cell therapies promising and potentially available off-the-shelf for hematological and solid tumor treatment, says GlobalData

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a wide range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in hematological indications is more advanced, there are a high number of therapies being investigated in […]
Read more

Axsome Therapeutics AXS-05 shows promising results in resistant depression treatment, says GlobalData

Axsome Therapeutics recently announced that its pipeline product AXS-05 (bupropion + dextromethorphan) achieved primary and key secondary endpoints in the MERIT Phase II Trial for the treatment of resistant depression (TRD). A large number of major depressive disorder (MDD) patients do not respond to the available treatments and are referred to as treatment-resistant. There is […]
Read more

Strong pipeline, favorable regulatory landscape to drive China biosimilar market, says GlobalData

China has seen a significant surge in biosimilar approvals over the last three years, with 13 new biosimilars approved during 2018–2021. Strong biosimilar pipeline and the latest regulation changes by the National Medical Products Administration (NMPA) are likely to drive China’s biosimilar market to new heights, says GlobalData, a leading data and analytics company. Prior […]
Read more

Biogen will establish strong presence in multiple sclerosis market through InnoCare Pharma collaboration

Biogen recently announced that it has entered into a license and collaboration agreement with InnoCare Pharma for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi), for the potential treatment of multiple sclerosis (MS). This new collaboration will enable Biogen to expand its MS pipeline portfolio, while also providing a potential treatment for MS […]
Read more

Disappointing setback for Kyowa’s Nouryant in the treatment of Parkinson’s disease in Europe, says GlobalData

While the EMA’s recent recommended rejection of Kyowa Kirin’s Parkinson’s disease (PD) drug Nouryant (istradefylline) may have come as a surprise, key opinion leaders interviewed by leading data and analytics company GlobalData had mixed views on the drug’s efficacy and safety as an add-on therapy. Kyowa Kirin needs to capitalize on Nouryant’s sales in the […]
Read more

Leading pharma companies entry into digital healthcare will bolster personalized care in India, says GlobalData

Since 2019, there has been an increase in the adoption of digital health technology in India, with collaborations between pharmaceutical companies, insurance companies, and digital health solution providers improving communication between patients and physicians, in turn improving the delivery of quality healthcare. This exciting space, which has attracted the likes of major Indian pharma companies, […]
Read more

BioMarin’s Roctavian could transform the treatment landscape for severe hemophilia A, says GlobalData

BioMarin’s Roctavian can significantly reduce the treatment burden on patients with severe hemophilia A Key opinion leaders believe that Roctavian’s benefit could decline over time in hemophilia patients If Roctavian is approved, BioMarin is projected to have a market share of 30% by 2027 BioMarin recently presented positive one-year results regarding its GENEr8-1 Phase III […]
Read more

Anticoagulation strategy for COVID-19 patients and important insights gained from hospitalized cases: reveals GlobalData

The prevention of thrombosis is one of many priorities in managing the COVID-19 patients, but there are several complex considerations, especially when examining anticoagulation strategies. General considerations include the dose of anticoagulant, anticoagulant drug/drug class choice, and treatment duration, as well as to whom and when to administer anticoagulation along with the disease spectrum, according […]
Read more

COVID-19 hospitalization costs impose substantial financial burden on Indian patients, says GlobalData

India’s public expenditure on healthcare has exposed weaknesses in its infrastructure, especially during the second wave of the COVID-19 pandemic. Against this backdrop, patients must rely on private hospitals, which is imposing a heavy economic burden on COVID-19 patients, says GlobalData, a leading data analytics and research company. In its FY 2021 Union Budget, India […]
Read more

Upcoming LBPs could be the answer for GI patients with no approved treatments, says GlobalData

Live biotherapeutic products (LBPs), which target microbial communities in the skin and gastrointestinal (GI) and respiratory tracts, are expected to offer hope to groups of irritable bowel syndrome patients that currently have no US- or EMA-approved treatment options, according to GlobalData. The leading data and analytics company highlights the example of 4D Pharma’s Blautix, which […]
Read more

Sales of anti-neoplastic agents for non-proliferative diabetic retinopathy will triple within two years, says GlobalData

There are more than nine pharmaceutical companies developing therapeutics that can be used to treat non-proliferative diabetic retinopathy (NPDR) in the nine major markets (9MM*), says GlobalData. According to the leading data and analytics company, sales of drugs launching between 2021 and 2028 for NPDR are expected to reach $1.8bn. According to GlobalData’s report, ‘Diabetic […]
Read more

Private equity firms are acquiring top CMOs at a rapid rate, says GlobalData

Acquisitions of pharmaceutical contract manufacturing organizations (CMOs) are increasing, and the most common type of acquirer is private equity (PE) firms, which view the industry as a prudent choice for a return on investment, according to GlobalData, a leading data and analytics company. The company’s report, ‘M&A in the Contract Manufacturing Industry: Implications and Outlook […]
Read more
1 … 58 59 60 61 62 … 108